NSE · Healthcare · Drug Manufacturers - General
EPS came in at 19.83 against a street estimate of 16.50 — a beat of 20.2%.
with an average price target of ₹3,097.25.
| Holder | Stake |
|---|---|
| Nippon Life India Trustee Ltd-a/c Nippon India Nif | 1.05% |
| Quant Mutual Fund-quant Elss Tax Saver Fund | 1.01% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call GLAXOSMITHKLINE PHARMACEUTICALS LIMITED – Q1 FY2027 SUMMARY HEADLINE NUMBERS • Sales: INR 924 crores, up 15% year-on-year • EBITDA: up 17% year-on-y | 2026-08-06 |
| Quarterly results · Q1 FY27 GLAXOSMITHKLINE PHARMACEUTICALS LIMITED – Q1 FY2026-27 SUMMARY HEADLINE NUMBERS • Standalone Revenue from Operations (Q1 FY26-27): Rs. 92,442 lakhs, | 2026-08-03 |
| Investor presentation · Q1 FY27 GSK INDIA Q1 FY27 - INVESTOR SUMMARY HEADLINE NUMBERS • Revenue: ₹924 crore, growth +15% YoY • PAT (Net Profit): ₹253 crore, growth +24% YoY with ma | 2026-08-03 |
| Annual report FY2026 GLAXOSMITHKLINE PHARMACEUTICALS LIMITED – ANNUAL REPORT FY2025-26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹3,790 Crores (FY2024-25: ₹3,7 | 2026-06-05 |
| Q4 FY26 earnings call GLAXOSMITHKLINE PHARMACEUTICALS LIMITED Q4 FY2026 & FULL YEAR EARNINGS SUMMARY --- HEADLINE NUMBERS • Full Year FY2026 Revenue Growth: 2% (muted du | 2026-05-18 |
| Investor presentation · Q4 FY26 GSK INDIA - INVESTOR SUMMARY HEADLINE NUMBERS • Revenue FY26: ₹3,790 Cr (+2% YoY) • PAT (before exceptional) FY26: ₹1,010 Cr (+10% YoY) – first-ever | 2026-05-13 |
| Quarterly results · Q4 FY26 GSK PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY FY 2025-26 (Year Ended 31st March 2026) --- HEADLINE NUMBERS • Revenue from operations (Consolidate | 2026-05-13 |
| Q3 FY26 earnings call GLAXOSMITHKLINE PHARMACEUTICALS LIMITED – Q3 FY2026 SUMMARY HEADLINE NUMBERS • Revenue (Standalone): INR 1,000+ crores – First time crossing this mi | 2026-02-16 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹57 / share ex-date May 29, 2026 | 2026-05-29 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GlaxoSmithKline Pharmaceuticals Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.